EULAR 2018 Coverage

Biosimilar Drugs

Nonmedical Switching in Rheumatic Disease: An Interview With Allan Gibofsky, MD

Allan Gibofsky, MD, shares insight on the cost associated with nonmedical switching in patients with rheumatic diseases.

EULAR 2018 Coverage

Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis

In biologic-naive patients with psoriatic arthritis who are treated with apremilast, early onset of effect was observed across disease PsA manifestations.

EULAR 2018 Coverage

Sprifermin Improved Cartilage Morphology, Thickness in Knee Osteoarthritis

Sprifermin has a positive effect on cartilage morphology and cartilage thickness in radiographic knee osteoarthritis.

EULAR 2018 Coverage

Allopurinol Medication Adherence Increased With Daily Text Message Reminders

Mobile phone text reminders could be an important tool to enhance medication adherence in people with gout.

EULAR 2018 Coverage

Depressive Symptom Onset Linked to Disease Severity in Knee OA

To effectively treat individuals with radiographic knee OA and comorbid depressive disorder, it is necessary to use a combined treatment strategy of 2 interventions delivered in parallel to simultaneously target each condition.

EULAR 2018 Coverage

Infliximab May Lower Glucocorticoid Requirements, Lead to Remission in Takayasu Arteritis

Treatment of active Takayasu arteritis with infliximab may result in remission or in a diminished requirement for glucocorticoids.

EULAR 2018 Coverage

RA Associated With Greater Reduction in Short-Term Disease Burden vs Osteoarthritis

Investigators analyzed MDHAQ/RAPID3 scores in patients with osteoarthritis or rheumatoid arthritis to assess disease burden associated with each rheumatic disease.

EULAR 2018 Coverage

Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA

The objective of this cross-sectional analysis was to evaluate the prevalence of osteoporosis and frequency of fractures in patients with psoriasis or psoriatic arthritis.

EULAR 2018 Coverage

SLE-DAS Superior to SLEDAI-2K in Detecting Changes in SLE Disease Activity

To assess validity of SLE-DAS, investigators performed a Spearman’s correlation between SLE-DAS, PGA, and SLEDAI-2K at the last follow-up visit.

EULAR 2018 Coverage

Low Tuberculosis Screening Rates Observed Among Patients Starting TNFis

Only about half of patients who started TNFi therapy were screened for tuberculosis prior to therapy initiation.